Eloxx Pharmaceuticals, Inc. — FY 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; filed March 12, 2021. This is an annual report, not a standalone fourth-quarter report. Eloxx is a clinical-stage biopharmaceutical company with no approved products and no product revenue.
Key financial metrics
| Metric | FY 2020 / Dec. 31, 2020 | FY 2019 / Dec. 31, 2019 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $14.6 million | $26.3 million |
| General and administrative expense | $14.8 million | $24.2 million |
| Restructuring expense | $4.0 million | None |
| Total operating expenses | $33.5 million | $50.6 million |
| Net loss | $34.6 million | $50.9 million |
| Net loss per share, basic and diluted | $0.86 | $1.34 |
| Net cash used in operating activities | $28.2 million | $39.4 million |
| Cash and cash equivalents | $24.7 million | $22.5 million |
| Total assets | $26.5 million | $58.9 million |
| Total debt carrying value | $11.6 million | $14.8 million |
No gross or operating margins are meaningful because the company reported no product revenue. The filing reports an accumulated deficit of $171.6 million at year-end 2020 and no income tax provision for 2020.
Material changes versus the prior comparable period
- Net loss narrowed by $16.3 million, or 32%, while total operating expenses declined $17.1 million, or 34%.
- R&D expense fell $11.8 million, primarily reflecting reduced personnel and external development spending following the February 2020 organizational realignment, as well as lower subcontractor and clinical-development costs amid COVID-19 disruptions.
- G&A expense declined $9.4 million, mainly due to lower stock-based compensation, professional and infrastructure costs, and personnel costs.
- The company recorded a one-time $4.0 million restructuring charge after eliminating 13 positions. This included $2.1 million of non-cash accelerated stock compensation and approximately $1.9 million of separation and contract-termination costs.
- Operating cash use decreased $11.2 million. Financing cash flow was a $3.4 million use in 2020, compared with $46.8 million provided in 2019, when the company raised equity and obtained term-loan proceeds.
- Cash and cash equivalents rose to $24.7 million, while marketable securities declined from $33.8 million to zero as securities matured. The cash-flow statement reports $33.8 million of maturity proceeds.
Business, outlook, risks, and unusual items
- Lead program: ELX-02, an investigational read-through drug candidate, is being studied in Phase 2 trials for cystic fibrosis (CF) patients with nonsense mutations. Enrollment was temporarily paused in 2020 because of COVID-19, then resumed in Europe and Israel in June and in the U.S. in August. Management expected top-line data in the first half of 2021, conditional on no further disruption; this is a stated target, not a guarantee.
- Cystinosis: Eloxx discontinued its Phase 2 study and did not proceed with the planned second cohort. Although the first cohort met its primary safety endpoint and showed indications of biological activity, uncontrolled pretreatment white-blood-cell cystine levels limited interpretation of treatment effects. Management said it would review the data and consider a possible revised study design.
- Pipeline: Preclinical work includes ADPKD and inherited retinal disorders, with an initial retinal focus on Usher syndrome. No other candidate was in clinical development at year-end. The company reported preclinical read-through activity, but such findings do not establish clinical efficacy.
- Liquidity and going concern: Management said year-end cash was expected to fund operations through CF Phase 2 top-line data, but was insufficient to support current and planned operations for at least 12 months after the 10-K filing. The company and auditor disclosed substantial doubt about the company’s ability to continue as a going concern without additional funding. Management plans to seek financing or strategic funding; availability is not assured.
- Debt: The term loan bears a floating rate (5.75% at year-end), with principal installments underway and amounts due by January 2023; it is secured by substantially all assets other than intellectual property. A $0.8 million PPP loan bears 1% interest and may be forgiven subject to program requirements and lender/SBA approval. The filing does not establish that forgiveness was obtained.
- Other funding and obligations: The Cystic Fibrosis Foundation had paid $0.8 million by year-end, recorded as an advance, with payments tied to program milestones and potential repayment obligations in specified circumstances. The company reported a further $2.6 million received in the first quarter of 2021, bringing receipts to $3.4 million. IIA grants also carry contingent royalties and possible additional obligations tied to certain transfers of technology.
- COVID-19 and execution risks: The pandemic affected trial enrollment and may continue to disrupt patient access, clinical-site operations, vendors, and regulatory timelines. Other central risks include clinical safety or efficacy failure, slow enrollment, reliance on third-party manufacturers and CROs, competition, regulatory approval uncertainty, and the need for substantial additional capital.
- Controls and legal matters: Management concluded disclosure controls and internal control over financial reporting were effective as of year-end. No material pending legal proceedings were reported.
Important facts for investors to verify
- Subsequent disclosures on CF Phase 2 enrollment, completion, safety, efficacy, and whether the first-half 2021 data target was met.
- Current cash runway, financing raised or available, and the company’s latest going-concern assessment.
- Outstanding term-loan and PPP balances, repayment schedule, collateral terms, and any approved PPP forgiveness.
- Whether CF Foundation milestone funding continues and whether any repayment or disposition-related obligations have been triggered.
- Plans and evidence supporting any redesigned cystinosis study, and the status of ADPKD and retinal preclinical programs.
- Potential dilution from future equity financing and stock awards; the filing reports 40.2 million common shares outstanding as of March 8, 2021.